BLAINJECTIONINJECTABLE
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
RYZNEUTA (efbemalenograstim alfa-vuxw) by Evive Biotech. Approved for ovarian cancer, cervical cancer. First approved in 2023.
Drug data last refreshed 20h ago
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Worked on RYZNEUTA at Evive Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.